Free Trial
NASDAQ:SKYE

Skye Bioscience (SKYE) Stock Price, News & Analysis

Skye Bioscience logo
$5.24
+0.15 (+2.95%)
(As of 06:32 PM ET)

About Skye Bioscience Stock (NASDAQ:SKYE)

Key Stats

Today's Range
$4.92
$5.28
50-Day Range
$3.55
$5.24
52-Week Range
$1.44
$19.41
Volume
111,400 shs
Average Volume
179,199 shs
Market Capitalization
$158.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67
Consensus Rating
Buy

Company Overview

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
32nd Percentile Overall Score

SKYE MarketRank™: 

Skye Bioscience scored higher than 32% of companies evaluated by MarketBeat, and ranked 843rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Skye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Skye Bioscience has only been the subject of 4 research reports in the past 90 days.

  • Read more about Skye Bioscience's stock forecast and price target.
  • Percentage of Shares Shorted

    7.77% of the float of Skye Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Skye Bioscience has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Skye Bioscience has recently increased by 17.36%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Skye Bioscience does not currently pay a dividend.

  • Dividend Growth

    Skye Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.77% of the float of Skye Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Skye Bioscience has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Skye Bioscience has recently increased by 17.36%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Skye Bioscience has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Skye Bioscience this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,750,352.00 in company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of Skye Bioscience is held by insiders.

  • Percentage Held by Institutions

    Only 21.09% of the stock of Skye Bioscience is held by institutions.

  • Read more about Skye Bioscience's insider trading history.
Receive SKYE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SKYE Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 10/7 - 10/11 (SKYE)
Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings
Blue injector dosing pen for subcutaneous injection of antidiabetic medication, anti-obesity medication on a blue background. Measuring tape around the injector. Drug and weight loss — Photo
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
Hand turning a knob to select low risks investment. Concept of risk and reward ratio. Composite image between a hand photography and a 3D background.
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.
Skye Bioscience Appoints New Chairman for Strategic Growth
Skye Bioscience names Grayson as Chairman of the Board
See More Headlines

SKYE Stock Analysis - Frequently Asked Questions

Skye Bioscience's stock was trading at $2.72 at the start of the year. Since then, SKYE shares have increased by 92.6% and is now trading at $5.24.
View the best growth stocks for 2024 here
.

Skye Bioscience, Inc. (NASDAQ:SKYE) posted its quarterly earnings results on Friday, August, 9th. The company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20).

Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/09/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SKYE
Previous Symbol
NASDAQ:SKYE
Fax
N/A
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.67
High Stock Price Target
$25.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+269.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-37,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.17) per share

Miscellaneous

Free Float
29,428,000
Market Cap
$153.21 million
Optionable
Optionable
Beta
1.78
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:SKYE) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners